Research group - Katalin Dobra

We study the differentiation of malignant tumors of the lung and pleura and their molecular signature relating to biological properties such as proliferation and invasion. We identify biomarkers that allow early diagnosis and optimize conditions for individualized treatment.

Research group leader Katalin Dobra

Group members

Research techniques

  • Cell culture, establishment of primary cells
  • Molecular- and biochemical analyzes
  • Proteomics
  • Lighting and fluorescence microscopy
  • Ex-vivo susceptibility testing of primary tumor cells for cytotoxic substances and drugs

External funding

Research Council, the Swedish Cancer Society, AFA insurance, Heart-Lung Foundation, the Cancer Society in Stockholm, the Swedish Medical Society, Stockholm County Council (Research Fellow), KI Funds, Compass

Teaching assignments

We actively participate in the education of Medical- and Dental Student Programs and the Biomedical Analytical program

Selected publications

Diagnostic performance of a stepwise cytological algorithm for biliary malignancy in primary sclerosing cholangitis.
von Seth E, Ouchterlony H, Dobra K, Hjerpe A, Arnelo U, Haas S, et al
Liver Int. 2019 02;39(2):382-388

Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines.
Hjerpe A, Abd-Own S, Dobra K
Arch. Pathol. Lab. Med. 2018 08;142(8):893-901

Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma.
Heidari-Hamedani G, Vivès RR, Seffouh A, Afratis NA, Oosterhof A, van Kuppevelt TH, et al
Cell. Signal. 2015 Oct;27(10):2054-67

Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.
Szulkin A, Otvös R, Hillerdal CO, Celep A, Yousef-Fadhel E, Skribek H, et al
BMC Cancer 2014 Sep;14():709

Nuclear translocation of heparan sulfate proteoglycans and their functional significance.
Kovalszky I, Hjerpe A, Dobra K
Biochim. Biophys. Acta 2014 Aug;1840(8):2491-7

Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
Mundt F, Johansson HJ, Forshed J, Arslan S, Metintas M, Dobra K, et al
Mol. Cell Proteomics 2014 Mar;13(3):701-15

Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells.
Szatmári T, Mundt F, Heidari-Hamedani G, Zong F, Ferolla E, Alexeyenko A, et al
PLoS ONE 2012 ;7(10):e48091